Bristol-Myers Squibb Company (BMY) Financials
BMY Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 95.2 billion | 65.7 billion |
2023-09-30 | 91.3 billion | 62.2 billion |
2023-06-30 | 93.5 billion | 61.5 billion |
2023-03-31 | 94.3 billion | 62.4 billion |
BMY Free Cash Flow and Stock based compensation
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 3.9 billion | 127.0 million |
2023-09-30 | 4.4 billion | 132.0 million |
2023-06-30 | 1.6 billion | 137.0 million |
2023-03-31 | 2.7 billion | 122.0 million |
BMY Net Income
Date | Net Income |
---|---|
2023-12-31 | 1.8 billion |
2023-09-30 | 1.9 billion |
2023-06-30 | 2.1 billion |
2023-03-31 | 2.3 billion |
BMY Cash and Debt
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 12.3 billion | - | 1.7 billion |
2023-09-30 | 7.7 billion | 32.1 billion | 1.7 billion |
2023-06-30 | 8.4 billion | 34.7 billion | 1.5 billion |
2023-03-31 | 9.0 billion | 35.1 billion | 1.5 billion |
BMY Shares Outstanding
BMY Expenses
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 330.0 million | 2.5 billion | 2.1 billion | - |
2023-09-30 | 342.0 million | 2.2 billion | 1.9 billion | 2.0 billion |
2023-06-30 | 259.0 million | 2.3 billion | 1.9 billion | - |
2023-03-31 | 278.0 million | 2.3 billion | 1.8 billion | 1.8 billion |
BMY Cost of Revenue
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 11.5 billion | 2.7 billion |
2023-09-30 | 11.0 billion | 2.5 billion |
2023-06-30 | 11.2 billion | 2.9 billion |
2023-03-31 | 11.3 billion | 2.6 billion |
BMY
List: Contenders
Price: $48.93
Dividend Yield: 0.04%
Forward Dividend Yield: 4.90%
Payout Ratio: 62.18%
Dividend Per Share: 2.40 USD
Earnings Per Share: 3.80 USD
P/E Ratio: 12.90
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Volume: 10.2 million
Ebitda: 946.0 millionMarket Capitalization: 104.2 billion
Average Dividend Frequency: 4
Years Paying Dividends: 53
DGR3: 8.88%
DGR5: 7.07%
DGR10: 4.91%
DGR20: 3.52%